Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
about
Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infectionsEvaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratificationEmergence of Klebsiella pneumoniae carbapenemase-producing bacteriaThe pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenemFrom Bench-Top to Bedside: A Prospective In Vitro Antibiotic Combination Testing (iACT) Service to Guide the Selection of Rationally Optimized Antimicrobial Combinations against Extensively Drug Resistant (XDR) Gram Negative Bacteria (GNB)Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patientsImipenem resistance of Pseudomonas in pneumonia: a systematic literature reviewEvaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plagueDoes prolonged β-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials.Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimensExtensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations.Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumanniiIn vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae.Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams.Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.Pharmacokinetic/pharmacodynamic profiling of imipenem in patients admitted to an intensive care unit in India: A nonrandomized, cross-sectional, analytical, open-labeled study.Continuous beta-lactam infusion in critically ill patients: the clinical evidenceContinuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumoniaVariability in plasma concentration of cefotaxime in critically ill patients in an Intensive Care Unit of India and its pharmacodynamic outcome: A nonrandomized, prospective, open-label, analytical studyPooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluidReassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignanciesEfficacy of Lysophosphatidylcholine in Combination with Antimicrobial Agents against Acinetobacter baumannii in Experimental Murine Peritoneal Sepsis and Pneumonia Models.In Vitro Activity of Polymyxin B in Combination with Various Antibiotics against Extensively Drug-Resistant Enterobacter cloacae with Decreased Susceptibility to Polymyxin B.Clinical outcomes of patients with Klebsiella pneumoniae carbapenemase-producing K. pneumoniae after treatment with imipenem or meropenem.Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock--does the dose matter?Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model.Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients.β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.Drug absorption, distribution, metabolism and excretion considerations in critically ill adults.Using higher doses to compensate for tubing residuals in extended-infusion piperacillin-tazobactam.Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis.Role of therapeutic drug monitoring in pulmonary infections: use and potential for expanded use of dried blood spot samples.Carbapenem susceptibility breakpoints, clinical implications with the moving target.Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.Continuous and Prolonged Intravenous β-Lactam Dosing: Implications for the Clinical Laboratory.Prolonged versus Intermittent Infusion of β-Lactams for the Treatment of Nosocomial Pneumonia: A Meta-Analysis.A Human Biofilm-Disrupting Monoclonal Antibody Potentiates Antibiotic Efficacy in Rodent Models of both Staphylococcus aureus and Acinetobacter baumannii Infections.Impact of imipenem and amikacin pharmacokinetic/pharmacodynamic parameters on microbiological outcome of Gram-negative bacilli ventilator-associated pneumonia.In vitro pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase.
P2860
Q24199096-AB5B4AF3-3803-4538-A44D-9F16DBDFBD50Q24615937-08EC8F4D-3547-4F90-9088-B9A6163BD7CBQ24618178-21E757A7-938B-4C23-9C36-BCA73E00056AQ28289744-3199A421-5E7B-4CBD-9547-582B74A469AAQ28552767-996B2766-BCA9-4D38-A1CD-A13DE51D6C3DQ33552161-0A9217E2-8906-4969-A789-B9041B36308DQ33675546-1EDA0229-1C47-4F6A-A8AF-42113348DBC7Q33798021-6B6CBEB9-0270-402C-A317-8EECA76C4A89Q33940174-94D3DE5A-1257-4080-872D-BCDF62E664C7Q34570886-E0847A7E-0682-48D9-82F2-F1B20A43D442Q35041371-EA3858B4-3B44-46BC-95BD-D3C1ED66EB35Q35168931-F1494555-B7B0-4DD8-A389-2E5EFBC09B41Q35385713-1326D36C-468D-4295-AF0E-AC8EFFDA4513Q35908084-56BCB4C8-88ED-4FD8-A61A-916EB65FE1F5Q36078359-6D835D6B-51A6-4E55-9AD3-D30834E16637Q36262753-B662C987-C0BB-44F7-84B4-A9EAA9FA640DQ36329228-9E88D9DC-A115-4638-8DB0-80CB5C86C7AEQ36422575-55D3E398-22AA-4C56-B75C-1D341788C32CQ36797704-68CBF509-0EBD-4C5E-9988-B0B6B84ED90BQ36924714-19F01ACB-14E8-4465-856C-519B3161242FQ37072039-683E93F4-00C1-4EF7-890B-C360AD16A0EEQ37120088-35CE17B4-6890-4845-9F08-0467267621F0Q37203872-7B54FA59-DF9F-450C-8643-38251F1BF649Q37392989-A83B5854-241A-4720-A9E8-ACBCC64122D9Q37516599-BC4FA697-2351-4EA8-964C-0F8842E2F2A9Q37538623-98B6172B-E73A-4CDE-9362-25814E72E83AQ37538693-1917019C-3681-4656-B5EB-7A9D897FDBCCQ37867260-1C6F5B32-FC75-4171-8B24-D8A70689D675Q38004063-A4435788-70F6-4CE1-AC6D-705734AE3704Q38107537-6B771E15-348C-43D4-A0B6-76716B1A1871Q38110142-975ADB7E-95CA-41C2-9FCC-6B2995A1F447Q38167345-1653E61F-6B2E-4490-9B1D-D0753E531AA8Q38369608-14032BAE-F035-4581-803B-B50C0F455FD3Q38751264-20EFFE23-6237-4FBF-B731-4D85BF595656Q38838763-151F7D53-5EDB-4A2F-BC88-425A87845E8AQ38896040-3E6C64DD-4199-4424-9658-7A95A6CB606BQ39586044-8A6FF135-B591-4D15-8E26-9BC44AB520D2Q40131084-FCFF174C-C9F4-458A-A6AC-BEAA23E34E5BQ41516734-8DE444DE-A514-4C8D-ABCA-2A1AD0D374D1Q41858894-53ECCBD3-8137-4406-A59A-5F0AD3029D11
P2860
Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Population pharmacokinetics an ...... randomized, controlled trial.
@ast
Population pharmacokinetics an ...... randomized, controlled trial.
@en
type
label
Population pharmacokinetics an ...... randomized, controlled trial.
@ast
Population pharmacokinetics an ...... randomized, controlled trial.
@en
prefLabel
Population pharmacokinetics an ...... randomized, controlled trial.
@ast
Population pharmacokinetics an ...... randomized, controlled trial.
@en
P2093
P2860
P356
P1476
Population pharmacokinetics an ...... randomized, controlled trial.
@en
P2093
Anna K Glauner
Fritz Sörgel
George L Drusano
Martina Kinzig-Schippers
Samir G Sakka
Wolfgang Pfister
P2860
P304
P356
10.1128/AAC.01318-06
P407
P577
2007-07-09T00:00:00Z